So it is not currently complain with bid price requirement

Yes, that's correct. As of the latest data, Imunon Inc. (IMNN) is not currently compliant with the NASDAQ bid price requirement. However, the company has taken steps to address this issue.

1. **Non-Compliance**: IMNN was notified of its non-compliance with the minimum bid price requirement in November 2024 and had a 180-day grace period to rectify the situation. The company received a deficiency letter in May 2025 regarding its failure to meet the minimum stockholders’ equity requirement, which is a separate basis for delisting.
2. **Private Placement**: To address the bid price requirement, IMNN recently closed a private placement raising approximately $3.25 million. This includes the sale of 7.22 million common shares at a purchase price of $0.45 each, along with short-term warrants to purchase up to an additional 14.44 million shares. This financing effort is a significant step towards regaining compliance with NASDAQ's listing requirements.
3. **Ongoing Compliance Efforts**: IMNN plans to appeal the delisting determination and seeks to delay the delisting process while working towards regaining compliance, possibly through a reverse stock split, pending board and shareholder approval. The company is also actively pursuing non-dilutive funding and partnerships to support its clinical timelines and strategic objectives.

In summary, while IMNN is not currently compliant with the NASDAQ bid price requirement, the company is taking proactive measures to address the issue through a private placement and appeal process. The outcome of these efforts will be crucial in determining IMNN's future compliance status.